Skip to content

North Carolina Medicaid

Does North Carolina Medicaid cover Wegovy for Heart Disease Risk Reduction?

Yes. North Carolina Medicaid covers Wegovy for heart disease risk reduction with prior authorization if your BMI is 27 or higher. Other policy requirements and your plan's benefits also apply.

Policy on file; the document isn't available to view online yet.

  • Medicaid: Covered with requirements. See the qualification pathways below.

Earliest policy review June 4, 2026. How we verify · Check your exact plan

Full requirements: Wegovy for Heart Disease Risk Reduction (1 plan type)

Applies to Medicaid plans.

Covered with requirements

Qualification pathways

You can qualify through any one of these.

Cardioprotection (CV risk reduction) — Adult ≥ 45 with established CVD and BMI ≥ 27

All of:

  • Beneficiary is 45 years of age or older
  • Documented baseline BMI ≥ 27 kg/m² prior to beginning GLP-1 therapy
  • Established cardiovascular disease (CVD) defined as history of myocardial infarction, stroke, or symptomatic peripheral arterial disease — documented on PA form
  • No personal or family history of medullary thyroid carcinoma
  • No multiple endocrine neoplasia syndrome type 2
  • At least 3 months of lifestyle modifications prior to starting Wegovy
  • Currently on and will continue lifestyle modification including structured nutrition and physical activity
  • Will NOT use in combination with another GLP-1 receptor agonist
  • No FDA-labeled contraindications

Documentation to bring

  • Documented baseline BMI ≥ 27 kg/m² prior to beginning GLP-1 therapy (on PA form)
  • Documentation of established CVD (history of MI, stroke, or symptomatic peripheral arterial disease) on PA form
  • Documentation of at least 3 months of lifestyle modifications prior to starting Wegovy
  • Beneficiary age ≥ 45 confirmed

Quantity limits

  • titration doses — 2 mL per 28 days
  • maintenance doses — 3 mL per 28 days

Approval and renewal

  • Initial approval: 6 months
  • Renewal: every 6 months
  • Renewal: Medical documentation that beneficiary has improved while on medication AND individual clinical goals set by provider are being met OR beneficiary is continuing to make adequate progress towards treatment goals. Continued lifestyle modification required. No combination with another GLP-1. No FDA-labeled contraindications. Provider must document review of medication list at each renewal for possible dose reductions or discontinuation of comorbid medications. Note: Covered indication went into effect October 1, 2025; prior PA approval through Medicaid required before renewal.

Not covered when

  • Personal or family history of medullary thyroid carcinoma
  • Multiple endocrine neoplasia syndrome type 2 (MEN2)
  • Concurrent use with another GLP-1 receptor agonist
  • Pregnancy

Policy note: This cardioprotection/CV risk reduction indication is also accessible via the general weight management pathway for adults ≥ 45 with BMI ≥ 27 and established CVD. The Wegovy-specific cardioprotection section adds the requirement of at least 3 months of prior lifestyle modifications before starting therapy. Covered indication under Wegovy-specific criteria went into effect October 1, 2025 per the renewal criteria section. Duration of approval for Wegovy-specific indications (cardioprotection, MASH) is 6 months for initial and renewals.

Policy effective August 1, 2024 · verified June 4, 2026 · source: North Carolina Medicaid Medicaid prior authorization policy

Open on its own page →

Questions people ask
Does North Carolina Medicaid cover Wegovy?
Yes. North Carolina Medicaid covers Wegovy for heart disease risk reduction with prior authorization if your BMI is 27 or higher. Other policy requirements and your plan's benefits also apply.
How long does a Wegovy approval last with North Carolina Medicaid?
Heart Disease Risk Reduction — Applies to Medicaid plans. Initial approval: 6 months. Renewal: every 6 months.
What does North Carolina Medicaid require to renew Wegovy?
Heart Disease Risk Reduction — Applies to Medicaid plans. Medical documentation that beneficiary has improved while on medication AND individual clinical goals set by provider are being met OR beneficiary is continuing to make adequate progress towards treatment goals. Continued lifestyle modification required. No combination with another GLP-1. No FDA-labeled contraindications. Provider must document review of medication list at each renewal for possible dose reductions or discontinuation of comorbid medications. Note: Covered indication went into effect October 1, 2025; prior PA approval through Medicaid required before renewal.
How current is this information?
The oldest review date among the policies on this page is June 4, 2026. Each policy's effective and verification dates appear with its requirements. Confirm current benefits with your plan.

Also under North Carolina Medicaid: Zepbound

Wegovy under other plans: BCBS North Carolina, Alabama Medicaid, California Medicaid, Clover Health, Colorado Medicaid, Connecticut Medicaid, Delaware Medicaid, EmblemHealth

All insurance plans · All medications

Summary of North Carolina Medicaid's written policy, not a guarantee of coverage. Plans vary by employer and benefit design.